- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full International Business Machines Ratings Report.
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Here's what you need to know now for Wed., Aug. 9.
All eyes are on Pfizer in the months ahead.